Senate-Passed FDA Bill Includes More Drug Import Oversight
Increased Food and Drug Administration oversight of imported pharmaceuticals is a key feature of the FDA funding bill, called the FDA Safety & Innovation Act, S-3187, approved by the Senate 96-1 May 24. The bill still awaits House action. The…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
FDA has traditionally focused its inspections on U.S. factories, but about 80 percent of the ingredients used in U.S. medicines are now made overseas, officials said. Among other things, the bill would increase inspections of foreign drug manufacturers, require foreign manufacturers to register additional information about their facilities with the FDA and enhance penalties for drug counterfeiting.